Jade Biosciences (JBIO) Stock Price, News & Analysis

Company Overview

Jade Biosciences, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation. Preclinical studies have demonstrated promising activity in models of atopic dermatitis, psoriasis‐associated itch and other dermatologic conditions, supporting the progression of these candidates into human trials. Jade Biosciences’ pipeline strategy includes both topical and systemic formulations to broaden the therapeutic scope across multiple indications.

Founded in the mid‐2010s and incorporated in Delaware, Jade Biosciences maintains its headquarters in New Haven, Connecticut. The company’s management team draws on experience from established pharmaceutical and biotechnology organizations, combining expertise in medicinal chemistry, dermatology and clinical development. Listed on the Nasdaq under the ticker JBIO, Jade Biosciences is working to advance its pipeline through clinical milestones while preparing for potential partnerships and regulatory filings in the United States and other key markets.

Key Stats

• Today's Range: $15.93 to $18.84
• 50-Day Range: $13.26 to $26.85
• 52-Week Range: $6.57 to $28.00
• Volume: 3.50 million shs
• Average Volume: 619,569 shs
• Market Capitalization: $875.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.43
• Consensus Rating: Moderate Buy

Jade Biosciences Stock Analysis - MarketRank™

Jade Biosciences scored higher than 51% of companies evaluated by MarketBeat, and ranked 562nd out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Jade Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Jade Biosciences has a consensus price target of $47.43, representing about 167.4% upside from its current price of $17.74.

Amount of Analyst Coverage

Jade Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Jade Biosciences are expected to decrease in the coming year, from ($2.54) to ($2.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Jade Biosciences is -8.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jade Biosciences is -8.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Jade Biosciences has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.95% of the float of Jade Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Jade Biosciences has a short interest ratio ("days to cover") of 7.66.

Change versus previous month

Short interest in Jade Biosciences has recently increased by 9.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jade Biosciences does not currently pay a dividend.

Dividend Growth

Jade Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.43

News Sentiment

Jade Biosciences has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for Jade Biosciences this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for JBIO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

2 people have added Jade Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jade Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.06% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Jade Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JBIO
• Previous Symbol: NASDAQ:JBIO
• CIK: 1798749
• Web: N/A
• Phone: (617) 443-2400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Jade Biosciences: $47.43
• High Price Target: $74.00
• Low Price Target: $16.00
• Potential Upside/Downside: +167.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.34%
• Return on Assets: -47.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.29
• Quick Ratio: 14.29

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.74 per share
• Price / Book: 2.63

Miscellaneous

• Outstanding Shares: 49,360,000
• Free Float: 37,978,000
• Market Cap: $875.65 million
• Optionable: N/A
• Beta: 1.44